Fig. 1
From: Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
A diagram showing the novel epigenetic approaches inhibiting HER3 for cancer treatment. The class I HDACi entinostat potently downregulates HER3 expression via induction of miR-125a, miR-125b, and miR-205, which act in concert to inhibit HER3 protein translation. Thus, the epigenetic strategy takes advantage of a novel mechanism of action (distinct from that of an anti-HER3 Ab) to abrogate HER3 signaling